Background:  This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK- 1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF. Sponsor: Merck Sharp & Dohme Corp. Trial Registration No: NCT02861534 ( Link  Trial Status: recruiting, randomized worldwide Enrolling Centers:  Worldwide: 41 countries Core Study Team: 
© Christian Mueller, 2012 - 2018 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: November 2018
Jasmin Martin Home News Team Studies Publications Events Cooperations Contact Bettina Glatz VICTORIA Dr. Dayana Flores Beate Hartmann Ph.D. Thomas Stoll Eleni Michou